Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers

Rosiglitazone (rosi) is a powerful insulin sensitizer, but serious toxicities have curtailed its widespread clinical use. Rosi functions as a high-affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ), the adipocyte-predominant nuclear receptor (NR). The classic model, involving b...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Step, Sonia E., Lim, Hee-Woong, Marinis, Jill M., Prokesch, Andreas, Steger, David J., You, Seo-Hee, Won, Kyoung-Jae, Lazar, Mitchell A.
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory Press 2014
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4018489/
https://ncbi.nlm.nih.gov/pubmed/24788520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.237628.114
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars